Hanmi Surprises Again, Signing Big Diabetes Deal With Sanofi
This article was originally published in PharmAsia News
South Korea's Hanmi Pharmaceutical is making the history books. Following its record-setting agreements with Lilly and Boehringer Ingelheim earlier this year, it has now inked a substantially bigger licensing out pact worth up to €3.9bn with Sanofi for its diabetes Quantum Project. While the deal will buoy the portfolio of the leading global diabetes player, it offers no quick fix, analysts caution.
Register for our free email digests: